7 results about "Specific immune cell" patented technology

This disclosure relates to KRAS immunogenic peptides and their uses. According to this disclosure, the KRAS immunogenic peptides selectively bind to MHC class II in a preferential mode to selectively enhance the immunogenicity of specific immune cells capable of killing cancer cells, and thus can be advantageously used as superior cancer vaccines for the prevention and / or treatment of cancer by minimizing immune escape mechanisms of cancer cells.

The present application relates to the field of biological medicine, and provide a kind of bispecific antibody and its application, the bispecific antibody includes: first binding region, the first binding region has Ly6G6D binding activity, and second binding region, the second binding region has 4-1BB binding activity;Wherein, the first binding region includes Fab region, the second binding region includes VHH, the first binding region and the second binding region are connected.According to the 4-1BB x Ly6G6D bispecific antibody of the embodiment of the present application, 4-1BB has Ly6G6D-dependent agonism in the presence of Ly6G6D-positive tumor cells, so as to be able to activate tumor-specific immune cells, play anti-tumor effect while minimizing systemic toxicity, and is expected to provide a new treatment option for cancer patients, and has high clinical value.

This application discloses a CD4 + T cell-derived tsRNA biomarkers and their applications, wherein the biomarkers are derived from CD4 + A phenylalanine-tRNA fragment from T cells, wherein the phenylalanine-tRNA fragment is 5'tiRNA-36-PheGAA-8, and the nucleotide sequence of the 5'tiRNA-36-PheGAA-8 is shown in SEQ ID NO:5. This application relates to purified pathogenic CD4+ from MG patients. + T cell tsRNA sequencing significantly reduced background noise caused by cellular heterogeneity, providing more reliable data support for elucidating the regulatory mechanisms of tsRNA at the level of specific immune cells, and screening for CD4+ in MG patients. + The abnormally elevated expression of biomarkers in T cells facilitates dynamic monitoring of patients.

An immune cell having membrane-bound IL-21 (mbIL-21), and a preparation method therefor and a use thereof are provided. Specifically, mbIL-21 can be used in immunotherapy. mbIL-21 can enhance the expansion capability and killing power of specific immune cells, thereby enhancing the effect of NK cell therapy.

A method of detecting and / or measuring target specific immune cell response to an immune cell target in a sample containing more than one cell, the method comprising the steps of: (a) providing a sample droplet comprising a portion of the sample, wherein the sample droplet is configured to comprise more than one cell but statistically one or less than one immune cell specific for the target; (b) contacting an immune cell target with the sample droplet to form an incubation droplet; and (c) determining the response of a detection agent present in the incubation droplet.

The present invention provides a method for analyzing samples from one or more individuals to determine the presence or absence of immune cells capable of binding to antigen peptides. It also provides a method for detecting or treating cancer or tumors, pathogenic infections, or autoimmune diseases. Further, it provides a display portion having particles to which multiple MHC-peptide complexes are bound, with at least two of the MHC-peptide complexes being distinct. Additionally, it provides a bait composition having multiple display portions, and a method for analyzing immune cells by using the display portions or the bait composition as a screening tool.

This disclosure relates to a tumor immunotherapy composition, preparation method, and application based on specific immune cells, particularly specific immune cells activated by attenuated Listeria monocytogenes carrying non-integrating antigenic peptide plasmids. The disclosure involves extracting T cells in vitro, co-culturing T cells with antigen-presenting cells activated by attenuated Listeria monocytogenes, and generating T cells with specific tumor antigenic peptides in vitro. These specific T cells are then reinfused into the body to generate a tumor-specific immune response. The technical solution of this disclosure can specifically activate tumor-specific T cells, thereby triggering a series of anti-tumor immune responses. Furthermore, the process does not require genetic modification of autologous cells, significantly improving both targeting and safety.